|
Novel COX-2 inhibitor stirs hope, controversy: experts disagree over whether this drug exonerates the coxib of its role in MI and GI adverse effects.(Rx)
Publication: Internal Medicine News Publication Date: 15-NOV-04 Author: McNamara, Damian
|
|
|
|
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
|
|
|
COPYRIGHT 2004 International Medical News Group
Lumiracoxib significantly reduced ulcer complications, compared with naproxen and ibuprofen, without increasing serious cardiovascular events, according to analyses of a large randomized controlled trial of patients with osteoarthritis.
But experts sharply disagree on whether the findings on this latest addition to the class of selective cyclo-oxygenase 2 (COX-2) inhibitors truly exonerate the coxib of its role in potentiating myocardial infarctions and gastrointestinal adverse effects.
Such outcomes from lumiracoxib were published just as Merck & Co. announced the worldwide market withdrawal of its COX-2 inhibitor, rofecoxib, and as clinicians and researchers are questioning whether the effectiveness of the entire class outweighs concerns about safety. Previous...
Read the full article for free courtesy of your local library.
|
|
|
|
 |
| More Articles from Internal Medicine News |
Super bass-o-matic redux.(INDICATIONS)(Brief Article)
November 15, 2004
|
Federal agencies tackle challenge of obesity.(Practice Trends)
November 15, 2004
|
Insurers push use of evidence-based medicine.(Practice Trends)
November 15, 2004
|
Preparing for maternity and paternity leave.(THE REST OF YOUR LIFE)
November 15, 2004
|
'Face-to-face' DME prescribing proposal slammed.(Practice Trends)
November 15, 2004
|
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
